US Bancorp DE grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 233,073 shares of the company’s stock after purchasing an additional 6,120 shares during the period. US Bancorp DE’s holdings in Novo Nordisk A/S were worth $12,510,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Aperio Group LLC grew its holdings in shares of Novo Nordisk A/S by 12.0% in the 4th quarter. Aperio Group LLC now owns 897,599 shares of the company’s stock worth $48,174,000 after acquiring an additional 96,031 shares during the period. North Star Asset Management Inc. acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $1,194,000. Traynor Capital Management Inc. grew its holdings in Novo Nordisk A/S by 4.3% during the 4th quarter. Traynor Capital Management Inc. now owns 64,573 shares of the company’s stock valued at $3,465,000 after buying an additional 2,663 shares during the last quarter. Dean Capital Investments Management LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $218,000. Finally, Lakeview Capital Partners LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $204,000. Institutional investors own 6.16% of the company’s stock.
Shares of Novo Nordisk A/S (NVO) traded up $0.24 on Wednesday, hitting $50.39. The company had a trading volume of 447,121 shares, compared to its average volume of 1,482,905. The stock has a market cap of $98,540.00, a price-to-earnings ratio of 19.76, a P/E/G ratio of 3.26 and a beta of 0.57. Novo Nordisk A/S has a twelve month low of $32.89 and a twelve month high of $58.37.
The company also recently announced a special dividend, which will be paid on Tuesday, April 3rd. Investors of record on Monday, March 26th will be given a $0.8117 dividend. This represents a dividend yield of 0.96%. The ex-dividend date is Friday, March 23rd. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 32.16%.
Novo Nordisk A/S declared that its Board of Directors has authorized a stock repurchase program on Thursday, February 1st that permits the company to repurchase outstanding shares. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.
A number of brokerages have commented on NVO. Zacks Investment Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a report on Tuesday, January 2nd. Bank of America raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, December 6th. JPMorgan Chase & Co. raised Novo Nordisk A/S from an “underweight” rating to a “neutral” rating in a research note on Friday, December 29th. Deutsche Bank reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Monday, January 8th. Finally, Morgan Stanley raised Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. Novo Nordisk A/S presently has an average rating of “Hold” and an average target price of $64.00.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/14/us-bancorp-de-raises-position-in-novo-nordisk-a-s-nvo.html.
Novo Nordisk A/S Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.